Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSS-B8
- Development stage
- Unknown
- Lead developer
- Tianjin University of Traditional Chinese Medicine
- Modality
- Small Molecules
01
Overview
DSS-B8: sourced facts only. name: "In-depth mechanistic studies revealed that DSS-B8 functions as a vitamin D receptor agonist without inducing hypercalcemic effects." [PMID:37536216]; target: "In-depth mechanistic studies revealed that DSS-B8 functions as a vitamin D receptor agonist without inducing hypercalcemic effects." [PMID:37536216]; developer: "College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China." [PMID:37536216]; modality: "Collectively, our findings indicate that DSS-derived small molecules have considerable potential as clinically viable therapeutic strategies for β-catenin deactivation." [PMID:37536216]
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on DSS-B8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSS-B8.